Fagron has completed its acquisition of University Compounding Pharmacy (UCP), a California-based pharmaceutical compounder focused on the health and wellness segment. The transaction, initially announced in September 2025, strengthens Fagron’s presence in the United States, particularly in California, and expands its nationwide compounding platform across both patient-specific and outsourcing services. UCP, headquartered in San Diego, brings expertise in hormones and urology, along with a strong compliance record, and is highly complementary to Fagron’s existing business. The deal, valued at approximately $41.5 million, adds annual revenues of around $25 million, with Fagron expecting to realize synergies from the integration over the next 18 to 24 months.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fagron NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001158717-en) on January 12, 2026, and is solely responsible for the information contained therein.
Comments